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ABSTRACT
Children with primary immune deficiency (PID) who receive hematopoietic stem cell transplantation (HSCT)
often suffer from graft-versus-host disease (GVHD), which is commonly treated with corticosteroids (CS).
CS may cause hypertension, development of cardiac chamber hypertrophy (CCH), and left ventricular outflow
tract obstruction (LVOTO). We followed the development of CCH and LVOTO by serial echocardiograms in
10 children with PID before and 6 to 12 weeks after HSCT, and correlated their development with age of trans-
plant, GVHD, use of CS and hypertension. CCH developed in all 4 children transplanted before 1 year of age
who received high dose CS treatment for grade III or IV acute GVHD (aGVHD), but not in the 6 children
who were transplanted at later ages or who had not received high-dose CS (P 5 .07). Significant correlation
(P\ .002) was found between CCH and blood pressure measurements that deviated above the 99th percentile.
One child also suffered from severe LVOTO.CCHandLVOTO improvedwhenCS treatmentwas discontinued
and blood pressure normalized. We conclude that following HSCT, young children who suffer from aGVHD,
treated with high CS doses, and have excessive hypertension are at risk of developing CCH.
 2008 American Society for Blood and Marrow Transplantation
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Primary immune deficiency (PID) diseases are het-
erogeneous diseases that cause increased susceptibility
to infections in infancy, some of which are fatal unless
treated with allogeneic hematopoietic stem cell trans-
plantation (HSCT). Despite prophylaxis, acute graft-
versus-host-disease (aGVHD) occurs in 40% to 50%
or 70% to 80% of patients with severe immunodefi-
ciency who receive HSCT from family-related HLA
identical donors or HLA-matched unrelated donors,
respectively [1]. Corticosteroids (CS), often at high
doses, have been used to effectively treat aGVHD
[2]. Common side effects of CS, including hyperglyce-
mia, hypertension, and increased susceptibility to in-
fections, are well known. CS has also been associatedwith the development of cardiac chamber hypertrophy
(CCH).
CCH is characterized by thickening of the left ven-
triclewall, particularly the interventricular septum, and
is best identified by 2-dimensional echocardiogram
(2DE). CCH is most commonly caused by inherited
defects in sarcomere function with hypertrophic car-
diomyopathy [3]. Similar CCH has been described in
preterm, newborns, and infants treated with CS for
lung disease or hypsarrhythmia, many of whom also
suffered from hypertension [4,5]. CCH has also been
reported in young recipients of kidney transplants, pos-
sibly because of hypertension [6]. CCH may result in
left ventricular outflow tract obstruction (LVOTO)
and life-threatening arrhythmias.229
230 S. R. Bulley et al.CCHhas been reported, albeit rarely, afterHSCT,
typically in patients with conditions predisposing to
cardiac complications such as malignant infiltration
or inherited metabolic storage diseases [7,8]. CCH
and LVOTO were described in a single patient with
Krabbe disease, who receivedHSCT in the first month
of life [9]. However, the development of such compli-
cations after HSCT was not prospectively studied in
large groups of patients after HSCT.
Detailed in this report is the observation that CCH
may be associated with CS treatment for GVHD in
children with PID who undergo HSCT.
MATERIALS AND METHODS
Patients
Children diagnosed with PID according to the
World Health Organization (WHO) classification,
who received HSCT at the Hospital for Sick Children,
Toronto, Canada, betweenMarch 1, 2003, and Febru-
ary 28, 2007, were included in this study. Patients were
excluded if they did not have echocardiograms before
and/or after HSCT. Upon diagnosis, and until dis-
charge, patients were nursed in private laminar air
flow-filtered rooms with strict reverse isolation proce-
dures. Intravenous immunoglobulin infusions were
given to maintain IgG levels in the normal range for
age. High-calorie diet and prophylactic antibiotics
for Pneumocystis jiroveci were given. Children diag-
nosed with Omenn’s syndrome were treated with CS
or Cyclosporine A (CsA) prior to HSCT. All patients
received myeloablative conditioning with intravenous
busulphan followed by cyclophosphamide, each for
4 days. Engraftment was supported with granulo-
cyte-colony stimulating factor (G-CSF), which was
continued until the absolute neutrophil counts
(ANC) were .1  109 cells/L on 3 consecutive days.
After HSCT, the children received acyclovir, cotri-
moxazole, and Penicillin to prevent infections. Blood
samples were obtained weekly for DNA polymerase
chain reaction for herpes viruses including Epstein-
Barr virus (EBV) and cytomegalovirus (CMV).
GVHDprophylaxis includedCS (methylpredniso-
lone) 2mg/kg body weight/day andCsAwith doses ad-
justed to maintain levels between 100 to 150 or 150 to
200 mmol/L, after HSCT from family related or unre-
lated donors, respectively. The severity of aGVHD
was graded according to Glucksberg et al. Grade III
or IV aGVHDwas treated with 30 mg/kg/day methyl-
eprednisolone (MP) for 3 days, which were reduced ev-
ery 3 days to 20 mg/kg/day, 10 mg/kg/day, 5 mg/kg/
day, 3.75 mg/kg/day, and 2 mg/kg/day. Subsequently,
MP (or equal potency prednisone) was reduced by
25% on alternate days every 1 or 2 weeks for patients
after HSCT from related or unrelated donors, respec-
tively. When CS were given only on alternate days,
CsA was reduced by 25% to 33% every 2 weeks,followed by gradual reduction of the remaining CS.
Systolic blood pressures, determined when the patients
were not active, crying, or febrile, were maintained be-
low the 95th percentile for age with 1 or more of the
following: amlodipine, nifedipine, enalapril, nadolol,
or captopril. Acute GVHD (aGVHD) or chronic
GVHD (cGVHD) were documented on every fol-
low-up visit. None of the patients were lost to fol-
low-up. This prospective study was approved by the
Hospital for Sick Children, Toronto, Research Ethics
Board.
Echocardiography
All children had 2-dimensional echocardiograms
(2DE) 2 to 3 weeks prior to HSCT and 6 to 12 weeks
after HSCT. The echocardiograms were obtained
with commercially available equipment (High Defini-
tion Imager 5000, Philips Medical Systems, Canada)
using a 700-MHz transducer and analyzed by a single
cardiologist (L.B). Measurements included right and
left ventricular end-diastolic dimension, left ventricu-
lar end-systolic dimension, and interventricular
septum (IVS) and left ventricular posterior wall
(LVPW) thicknesses corrected for body surface area,
as previously described [10]. Left ventricular systolic
function was assessed by fractional shortening and
ejection fraction (EF). 2DE measurements were con-
sidered abnormal if theZ-scores were.3. TheZ-score
was calculated as: patient value minus normal popula-
tion mean/population standard deviation [10]. Dopp-
ler ultrasound was used to determine LVOTO,
which was defined as anatomic narrowing together
with a measured systolic gradient of .15 mmHg.
None of the children had evidence for familial hyper-
trophic cardiomyopathy or Pompe’s disease, Frie-
dreich’s ataxia, or Noonan’s syndrome, which have
also been associated with CCH.
Statistical Analysis
Correlation between patients’ age at transplant,
doses ofMP, frequency andmagnitude of hypertensive
episodes, and development of CCH, as measured by
LVPW and IVS Z-scores, were determined using
Spearman Correlation Coefficient. Cumulative MP
doses were calculating by multiplying the daily dose
(in milligrams equivalent toMP) and duration of treat-
ment between HSCT and the 2DE, divided by the pa-
tient’s weights. Three systolic blood pressure
measurements per day recorded in the patients’ charts
by the nursing team, at similar hours of the day be-
tween HSCT and the 2DE, were used to calculate
the frequency and deviation from the 95th and 99th
maximal blood pressure percentiles for age and height.
Crossclassified comparisons were analyzed by the
Fisher’s exact tests. Differences were considered statis-
tically significant if P\ .05.
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Patient Characteristics
Ten patients diagnosed with PID who received
HSCT were included in this study. Mutations in the
gamma common chain were the cause of the immuno-
deficiency in patients #1, #2, and #3. Four patients had
mutations in the Ribonuclease Mitochondrial RNA
Processing (patient #7), CD3d (patient #8), adenosine
deaminase (patient #9), or Wiskott-Aldrich syndrome
genes (#10). Two patients suffered fromOmenn’s syn-
drome without identifiable mutations. Five were
treated with CS prior to HSCT, including 3 with
Omenn’s phenotype (#4, #6, and #7). Patient #5
with Pneumocystis jiroveci pneumonia received 1 mg/
kg/day MP for 2 weeks, and another child (#10) with
Wiskott-Aldrich syndrome received a 3-day course
of 4 mg/kg/day MP for low platelet counts. Prior to
HSCT, 2DE demonstrated nonsignificant small pat-
ent foramen ovale in 2 children (# 4 and #8) and amitral
valve nodule in 1 patient (#9), which was determined to
be noninfectious. All had normal LVPW and IVS
thicknesses (Table 1) and normal ejection fraction
prior to HSCT (not shown).
HSCTwas performed at a median age of 6 months
(range: 5-19 months). Seven of the children received
bone marrow from HLA-matched or mismatched un-
related donors, 1 patient received bone marrow from
an HLA-identical family member, and 2 patients re-
ceived CD341 selected stem cells derived from periph-
eral blood lymphocytes (Table 1).
Complication and Outcome after HSCT
aGVHD grade III or higher was diagnosed in
1 and 6 patients after HSCT from family-related
or -unrelated donors, respectively (Table 1). Another
patient suffered skin grade I GVHD 32 days after
transplant. aGVHD of the skin was diagnosed clini-
cally, whereas aGVHD of the gastrointestinal system
and liver, which occurred in 4, were confirmed by
biopsies. aGVHD improved rapidly in all 7 patients
following 3 days of high-dose CS. All the children
who received high dose CS required 2 or more antihy-
pertensive medications.
Patient #2 was the only patient who did not sur-
vive. Five months after HSCT, while still receiving
weaning doses of CS, CsA, amlodipine, and nadolol,
he presented with vomiting and low-grade fever. He
rapidly deteriorated despite broad-spectrum antibiotic
treatment. Autopsy showed extensive myocarditis and
diffuse skeletal muscles myositis suggestive of toxic
shock-like syndrome. No infectious etiology was
identified.
Cardiac Chamber Hypertrophy after HSCT
CCH was diagnosed in 4 children after HSCT.
Three months after HSCT, patient #2 was found to Ta
b
le
1
.
P
at
ie
nt
C
ha
ra
ct
er
is
ti
cs
P
a
ti
e
n
t
#
LV
P
W
P
re
-H
S
C
T
Z
-s
c
o
re
IV
S
P
re
-H
S
C
T
Z
-s
c
o
re
A
g
e
o
f
H
S
C
T
(M
)
S
o
u
rc
e
o
f
H
S
C
T
(H
L
A
)
A
c
u
te
G
V
H
D
O
rg
a
n
,
S
e
v
e
ri
ty
(T
im
e
a
ft
e
r
H
S
C
T
)
H
ig
h
-
D
o
se
C
S
G
iv
e
n
A
n
ti
h
y
p
e
rt
e
n
si
v
e
M
e
d
ic
a
ti
o
n
s
O
u
tc
o
m
e
(T
im
e
a
ft
e
r
H
S
C
T
)
1
2
0
.2
9
2
1
.1
7
1
2
M
U
D
S
k
in
1
(3
2
d
a
y
s)
N
o
A
m
lo
d
ip
in
e
A
1
W
(1
8
M
)
2
0
.4
7
2
0
.4
7
8
M
U
D
S
k
in
2
,
li
v
e
r
3
,
(1
4
d
a
y
s)
Y
e
s
A
m
lo
d
ip
in
e
,
n
a
d
o
lo
l
D
ie
d
(5
M
)
3
2
1
.4
1
2
2
.3
9
1
9
M
is
M
U
D
P
B
L
N
o
N
o
N
o
A
1
c
h
ro
n
ic
sk
in
1
G
I
G
V
H
D
(9
M
)
4
0
.5
2
1
.1
9
6
M
U
D
S
k
in
3
,
G
I
2
,
(1
1
d
a
y
s)
Y
e
s
A
m
lo
d
ip
in
e
,
e
n
a
la
p
ri
l
A
1
sc
le
ro
d
e
rm
a
to
u
s
G
V
H
D
(4
0
M
)
5
0
.9
7
1
.6
8
1
3
M
U
D
S
k
in
4
,
(7
d
a
y
s)
Y
e
s
A
m
lo
d
ip
in
e
,
n
a
d
o
lo
l
A
1
W
(3
0
M
)
6
0
.6
9
0
.2
7
6
M
U
D
S
k
in
4
,
(9
d
a
y
s)
Y
e
s
A
m
lo
d
ip
in
e
,
e
n
a
la
p
ri
l,
n
a
d
o
lo
l
A
1
W
(2
5
M
)
7
1
.4
4
1
.3
2
6
M
is
M
U
D
L
iv
e
r
4
,
sk
in
4
,
G
I
3
,
(9
d
a
y
s)
Y
e
s
A
m
lo
d
ip
in
e
,
n
if
e
d
ip
in
e
,
e
n
a
la
p
ri
l,
h
y
d
ra
la
z
in
e
A
1
G
V
H
D
(3
M
)
8
0
.4
2
0
.8
0
5
M
U
D
S
k
in
4
,
(1
0
d
a
y
s)
Y
e
s
A
m
lo
d
ip
in
e
,
e
n
a
la
p
ri
l
A
1
W
(2
0
M
)
9
1
.8
9
0
.7
1
6
M
is
m
a
tc
h
e
d
re
la
te
d
P
B
L
N
o
N
o
a
m
lo
d
ip
in
e
A
1
d
e
a
fn
e
ss
,
d
e
v
e
lo
p
m
e
n
ta
l
d
e
la
y
(3
8
M
)
1
0
1
.5
1
1
.9
2
6
M
a
tc
h
e
d
re
la
te
d
S
k
in
2
,
li
v
e
r
2
,
(1
0
d
a
y
s)
Y
e
s
A
m
lo
d
ip
in
e
,
n
a
d
o
lo
l,
c
a
p
to
p
ri
l
A
1
W
(3
6
M
)
L
V
P
W
in
d
ic
at
es
le
ft
ve
n
tr
ic
le
p
o
st
er
io
r
w
al
lt
h
ic
kn
es
s;
IV
S
,i
n
te
rv
en
tr
ic
u
la
r
se
p
tu
m
th
ic
kn
es
s;
H
S
C
T
,h
em
at
o
p
o
ie
ti
c
st
em
ce
ll
tr
an
sp
la
n
ta
ti
o
n
;M
,m
o
n
th
s;
H
L
A
,h
u
m
an
le
u
ko
cy
te
an
ti
g
en
;M
U
D
,m
at
ch
ed
u
n
re
la
te
d
d
o
n
o
r;
P
B
L
,
C
D
34
1
fr
o
m
p
er
ip
h
er
al
b
lo
o
d
ly
m
p
h
o
cy
te
s;
G
V
H
D
,
gr
af
t-
ve
rs
u
s-
h
o
st
d
is
ea
se
;
A
,
al
iv
e;
W
,
w
el
l;
C
S
,
co
rt
ic
o
st
er
o
id
;
G
I,
ga
st
ro
in
te
st
in
al
tr
ac
t.
232 S. R. Bulley et al.have CCH without LVOTO. Although sequential
echocardiograms are not available, autopsy performed
2 months later showed persistent hypertrophy. Patient
#4 was found to have marked CCH and LVOTO with
a gradient of up to 85 mmHg across the aortic outlet,
3 months after HSCT. CS doses and CsA were rapidly
tapered over 6 weeks and propanolol was added.
Repeat 2DE 3 months later demonstrated marked
improvement of the CCH and LVOTO (Figure 1A).
However, 14 months after the HSCT, a short viral
illness induced extensive sclerodermatous GVHD
involving the skin and lungs, which was treated with
30mg/mg/kgMP for 3 days. Echocardiogramwas per-
formed 3 weeks later, demonstrated worsening of the
CCH and LVOTO, which again improved with pro-
panolol treatment and reduction of CS (Figure 1B).
Patient #7 suffered severe aGVHD, which initially re-
sponded to high doses of CS. Exacerbation of the
aGVHD, which occurred during reduction of CS in
the first 2 months after HSCT, was treated with myco-
phenol mofetil (MMF), antithymocyte immunoglobu-
lin, and daclizumab. CCH was found 2 months after
transplant, with no evidence of LVOTO. Patient #10
was found to have CCHwithout LVOTO, 6 weeks af-
ter HSCT. Because of persistent low-grade skin and
gastrointestinal GVHD, CS treatment was gradually
reduced over 8 months, with improvement of the left
ventricular hypertrophy. Importantly, despite the de-velopment of CCH, Left ventricular ejection fractions
were normal in all children (63% to 82%) and repeated
electrocardiograms did not demonstrate abnormal
heart rate in any child. Also, right and left ventricular
end-diastolic dimension, left ventricular end-systolic
dimension, and fractional shortening remained normal
after HSCT (data not shown).
CCH developed in all 4 children transplanted be-
fore 1 year of agewho received high-doseCS treatment
for grade III or IV aGVHD, but not in the 6 children
who were transplanted at a later age or who had not
received high-dose CS (P 5 .07). There was negative
correlation between patients’ age and LVPW or IVS
Z-scores, r 5 20.53 and 20.39, respectively, which
did not reach statistical significance. There was no sig-
nificant correlation between LVPW or IVS Z-scores
and total amount of CS (Table 2), or between the fre-
quency and the cumulative blood pressure above the
95th percentile and CCH (data not shown). Positive
correlation was found between LVPW and IVS Z-
scores and the frequency of blood pressure above the
99th percentile, r 5 10.55 and 10.48, although they
did not reach statistical significance (Table 2). In
contrast, correlation between LVPW or IVS Z-scores
and cumulative blood pressure measurements above
the 99th percentile, r 5 0.88 and 0.87, respectively,
were statistically significant (P 5 .0008 and .0012,
respectively).Figure 1. Echocardiograms of patient #4. (A) Echocardiogram long axis views of the left ventricle demonstrating a thickened interventricular
septum (left), which improved 3 month later (right). (B) Schematic representation of left ventricular posterior wall (open squares) and interven-
tricular septum thickness (open triangles), in centimeters, and corticosteroids treatment (filled shapes) in doses equivalent tomethylprednisolone,
before and after hematopoietic stem cells transplantation.
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.DISCUSSION
Herein we describe the first series of 4 patients who
after HSCT developed CCH indistinguishable from
hypertrophic cardiomyopathy. The hypertrophic car-
diomyopathy phenotype is common among children
with inherited defects of myocardial function, Pompe’s
disease, Friedreich’s, ataxia, or Noonan’s syndrome.
However, the contribution of such inherited syn-
dromes andmutations in the sarcomere to the develop-
ment of CCH in the children under our care is
unlikely, as there were no other affected family mem-
bers, and 3 of the 4 patients with CCH had mutations
in genes that do not result in cardiac involvement. The
remaining patient had Omenn’s syndrome, which has
previously been associated with ventricular hypertro-
phy in 1 patient prior to HSCT, possibly secondary
to abnormal lymphocytes infiltrating the heart [11].
In contrast, our patient with Omenn’s syndrome de-
veloped CCH after HSCT, when T cell receptor anal-
ysis already demonstrated normal expansion (data not
shown). Thus, the cardiac hypertrophy in our patients
was not likely inherited or directly related to the im-
munodeficiency, but rather related to the procedure
or treatment that these children received.
Anthracyclines and mediastinal irradiation given
prior to HSCT have been reported to cause cardiac
complications including arrhythmia and heart failure
but not the development of cardiac hypertrophy [12].
Similarly, high doses of Cy can result in restrictive car-
diomyopathy but not CCH per se [13], which suggests
that the CCH in our cohort was not because of the
transplant itself.
There are several common factors in the manage-
ment of the children described herein, which may help
understand the development of CCH. All the patients
who developed CCH had received the transplant be-
fore 1 year of age, experienced aGVHD, were treated
with CsA and high doses of CS, and suffered from hy-
pertension. aGVHD of the heart is rare, and usually
manifests as pericardial effusions, rhythm abnormali-
ties, or coronary arteriosclerosis, but not CCH [14].
Treatment with the calcineurin inhibitors CsA or Ta-
crolimus after solid organ transplantations have been
associated with CCH, possibly by exacerbating hyper-
tension; however, the CsA doses used to prevent solid
organ rejection are typically greater than those given
after HSCT [15]. In addition, by interfering with
NFAT signaling, calcineurin inhibitors have actually
been proposed for prevention and treatment of CCH
[16]; therefore, it is unlikely that they were the major
factor in development of CCH in our cohort. There-
fore, we suspect that 1 or more of the remaining factors
contributed to the appearance of CCH. The associa-
tion between high doses of CS and CCH is well estab-
lished, primarily in preterm infants or in the first few
weeks of life, many of whom also suffer from
234 S. R. Bulley et al.hypertension [4,5,17]. CCH has also been reported in
very few older children treated with CS [18], although
not after HSCT. CS may contribute to the develop-
ment of CCH by 1 or more mechanisms. Steroids
may directly stimulate glucocorticoid and mineralo-
corticoid receptors in muscle cells, increase Ca21 cur-
rents, or alter gene expression, which may lead to
myocyte hypertrophy [19,20]. Alternatively, CS and
CsA induced hypertension may cause pressure over-
load, which stimulates myocyte hypertrophy [21]. Sup-
port for the contribution of hypertension to the CCH
in this cohort is the correlation that we found between
accumulative blood pressure beyond the 99th percen-
tile and heart wall thickness, which is similar to the re-
ports of left ventricular wall thickening in patients with
malignant hypertension [22]. Clonidine, often used to
treat hypertension, may further potentiate the effects
of CS on the development of cardiac hypertrophy
[23]. However, such mechanisms are unlikely to have
contributed to CCH in our cohort, as patients were
not treated with alpha-adrenergic agonists. Thus, our
data suggests that HSCT complicated by aGVHD
and treated with high doses of CS, directly or in con-
cert with some of the factors described above, and
hypertension, particularly in young children, is associ-
ated with the development of CCH.
Medications used to prevent or treat GVHD after
HSCT have many adverse effects, to which we now
add the possible development of CCH. However, as
also demonstrated in our cohort, aggressive treatment
of aGVHD is still the most common cause of death af-
ter HSCT in children with PID and other nonmalig-
nant diseases [1,24]. Furthermore, we demonstrated
reversal of the CCH and LVOTO upon improvement
of the GVHD, discontinuation of CS, and control of
hypertension, and none of the children experienced
life-threatening arrhythmia. Therefore, we suggest
that while continuing the use of CS for aGVHD after
HSCT for PID, follow-up echocardiograms should be
performed to detect the development of CCH, en-
abling appropriate adjustment of the immunosuppres-
sive therapy.
Many children, other than those with PID, un-
dergo HSCT and frequently receive immune suppres-
sion with CS or CsA and suffer from hypertension;
however, we are unaware of previous reports of
CCH in such patients. Patients with severe immune
defects typically present and are transplanted, at
a much younger age than most pediatric malignancies
or other inherited disease. Furthermore, because
GVHD is the most common cause of morbidity and
mortality after transplant for severe immune defects,
it is often treated more aggressively and with higher
doses of steroids than in patients transplanted for other
etiologies [1]. Therefore, to determine whether the
development of CCH is unique to our cohort, to pa-
tients with severe immune deficiency, or is overlookedin other populations, larger prospective studies in
young children receiving HSCT for other etiologies
will be required.
In conclusion, we demonstrate increased fre-
quency of CCH after HSCT for PID in children\1
year of age who developed aGVHD, were treated
with high doses of CS, and who suffered from hyper-
tension.
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